BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-07
196 industry Phase 2/3 trial readout(s) and 42 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2025-07-01 | FDA approval | approved | ELI LILLY CO LLY | KISUNLA | Approved 2025-07-01: KISUNLA (BLA761248 SUPPL4) |
| 2025-07-02 | FDA approval | approved | DIZAL | ZEGFROVY | Approved 2025-07-02: ZEGFROVY (NDA219839 ORIG1) |
| 2025-07-02 | FDA approval | approved | RENGENERON PHARMACEUTICALS, INC. | LYNOZYFIC | Approved 2025-07-02: LYNOZYFIC (BLA761400 ORIG1) |
| 2025-07-03 | FDA approval | approved | KALVISTA | EKTERLY | Approved 2025-07-03: EKTERLY (NDA219301 ORIG1) |
| 2025-07-03 | FDA approval | approved | AVYXA HOLDINGS | GOBARDEN | Approved 2025-07-03: GOBARDEN (NDA219014 ORIG1) |
| 2025-07-03 | FDA approval | approved | RECORDATI RARE | ISTURISA | Approved 2025-07-03: ISTURISA (NDA212801 SUPPL4) |
| 2025-07-07 | Complete response letter | complete response | Ultragenyx Pharmaceutical Inc. RARE | CRL 2025-07-07: Ultragenyx Pharmaceutical Inc. BL 125845 | |
| 2025-07-09 | FDA AdCom | held | AdCom 2025-07-09: Pediatric Advisory Committee (PAC) | ||
| 2025-07-09 | Complete response letter | complete response | Capricor, Inc. CAPR | your product, deramiocel | CRL 2025-07-09: Capricor, Inc. BL 125842 (your product, deramiocel) |
| 2025-07-10 | FDA approval | approved | TAKEDA PHARMS USA TAK | MOTEGRITY | Approved 2025-07-10: MOTEGRITY (NDA210166 SUPPL4) |
| 2025-07-10 | FDA approval | approved | PFIZER INC PFE | ELREXFIO | Approved 2025-07-10: ELREXFIO (BLA761345 SUPPL3) |
| 2025-07-11 | FDA approval | approved | BAYER HLTHCARE | KERENDIA | Approved 2025-07-11: KERENDIA (NDA215341 SUPPL9) |
| 2025-07-15 | FDA approval | approved | BIOCON BIOLOGICS INC | KIRSTY | Approved 2025-07-15: KIRSTY (BLA761188 ORIG1) |
| 2025-07-16 | FDA approval | approved | FRESENIUS KABI USA | GLYCOPYRROLATE | Approved 2025-07-16: GLYCOPYRROLATE (NDA214919 SUPPL2) |
| 2025-07-16 | FDA approval | approved | SAGENT | FAMOTIDINE | Approved 2025-07-16: FAMOTIDINE (NDA219935 ORIG1) |
| 2025-07-16 | FDA approval | approved | HIKMA | ROBINUL | Approved 2025-07-16: ROBINUL (NDA017558 SUPPL68) |
| 2025-07-16 | FDA approval | approved | EXELA PHARMA | GLYRX-PF | Approved 2025-07-16: GLYRX-PF (NDA210997 SUPPL8) |
| 2025-07-17 | FDA AdCom | held | GlaxoSmithKline LLC | AdCom 2025-07-17: Oncologic Drugs Advisory Committee - BLA 761440 | |
| 2025-07-18 | FDA AdCom | held | Otsuka Pharmaceutical Company, Ltd. | AdCom 2025-07-18: Psychopharmacologic Drugs Advisory Committee - sNDA 205422/S-012 | |
| 2025-07-21 | Complete response letter | complete response | Replimune, Inc. REPL | vusolimogene oderparepvec | CRL 2025-07-21: Replimune, Inc. BL 125827 (vusolimogene oderparepvec) |
| 2025-07-23 | FDA approval | approved | ROSEMONT PHARMS | VOSTALLY | Approved 2025-07-23: VOSTALLY (NDA219757 ORIG1) |
| 2025-07-23 | FDA approval | approved | AMGEN INC AMGN | OTEZLA | Approved 2025-07-23: OTEZLA (NDA205437 SUPPL14) |
| 2025-07-23 | FDA approval | approved | ALTATHERA PHARMS LLC | SOTALOL HYDROCHLORIDE | Approved 2025-07-23: SOTALOL HYDROCHLORIDE (NDA022306 SUPPL8) |
| 2025-07-23 | FDA approval | approved | LEO PHARMA AS | ANZUPGO | Approved 2025-07-23: ANZUPGO (NDA219155 ORIG1) |
| 2025-07-24 | FDA approval | approved | AKARX INC | DOPTELET SPRINKLE | Approved 2025-07-24: DOPTELET SPRINKLE (NDA219696 ORIG1) |
| 2025-07-24 | FDA approval | approved | AKARX INC | DOPTELET | Approved 2025-07-24: DOPTELET (NDA210238 SUPPL10) |
| 2025-07-24 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2025-07-24: KEYTRUDA (BLA125514 SUPPL178) |
| 2025-07-24 | FDA approval | approved | BRILLIAN PHARMA | SDAMLO | Approved 2025-07-24: SDAMLO (NDA219531 ORIG1) |
| 2025-07-25 | FDA approval | approved | ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S ASND | SKYTROFA | Approved 2025-07-25: SKYTROFA (BLA761177 SUPPL8) |
| 2025-07-28 | Complete response letter | complete response | Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. | CRL 2025-07-28: Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. NDA 205508 | |
| 2025-07-28 | FDA approval | approved | APELLIS PHARMS | EMPAVELI | Approved 2025-07-28: EMPAVELI (NDA215014 SUPPL11) |
| 2025-07-28 | FDA approval | approved | JANSSEN THERAP | SIRTURO | Approved 2025-07-28: SIRTURO (NDA204384 SUPPL20) |
| 2025-07-28 | FDA approval | approved | PTC THERAP | SEPHIENCE | Approved 2025-07-28: SEPHIENCE (NDA219666 ORIG1) |
| 2025-07-29 | FDA approval | approved | CARWIN PHARM ASSOC | VYSCOXA | Approved 2025-07-29: VYSCOXA (NDA211759 ORIG1) |
| 2025-07-30 | Complete response letter | complete response | Teva Pharmaceuticals, Inc. TEVA | TVB-009 | CRL 2025-07-30: Teva Pharmaceuticals, Inc. BLA 761385 (TVB-009) |
| 2025-07-30 | Complete response letter | complete response | Regeneron Pharmaceuticals, Inc. REGN | CRL 2025-07-30: Regeneron Pharmaceuticals, Inc. BLA 761303 | |
| 2025-07-30 | Complete response letter | complete response | Conjupro Biotherapeutics Inc. | CRL 2025-07-30: Conjupro Biotherapeutics Inc. NDA 218923 | |
| 2025-07-30 | FDA approval | approved | ROSEMONT PHARMS | ATMEKSI | Approved 2025-07-30: ATMEKSI (NDA219843 ORIG1) |
| 2025-07-30 | FDA approval | approved | GILEAD SCIENCES INC GILD | BIKTARVY | Approved 2025-07-30: BIKTARVY (NDA210251 SUPPL23) |
| 2025-07-31 | FDA approval | approved | NOVO NORDISK INC NVO | ALHEMO | Approved 2025-07-31: ALHEMO (BLA761428 ORIG1) |
| 2025-07-31 | FDA approval | approved | LENZ THERAP LENZ | VIZZ | Approved 2025-07-31: VIZZ (NDA218585 ORIG1) |
| 2025-07-31 | FDA approval | approved | NOVARTIS NVS | LEQVIO | Approved 2025-07-31: LEQVIO (NDA214012 SUPPL16) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-07 est. | P2 | EMS | NCT02873468 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis | Eosinophilic Esophagitis | unknown | 116 |
| 2025-07 est. | P2 | Matrix Biomed, Inc. | NCT03480971 Treatment of Radiation and Cisplatin Induced Toxicities with Tempol | Mucositis; Nephrotoxicity; Ototoxicity | recruiting | 120 |
| 2025-07 est. | P2 | ImaginAb, Inc. | NCT05013099 Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies | Melanoma; Merkel Cell Carcinoma, Unspecified; Renal Cell Carcinoma; Non Small Cell Lung Cancer | unknown | 70 |
| 2025-07 est. | P2 | Adaptive Phage Therapeutics, Inc. | NCT05269134 Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI) | Prosthetic Joint Infection | withdrawn | |
| 2025-07 est. | P3 | Vanda Pharmaceuticals VNDA | NCT05361707 Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances | Autism Spectrum Disorder; Sleep Disorder; Neurological Disorder; Sleep Disturbance | unknown | 100 |
| 2025-07 est. | P1/P2 | Smart Immune SAS | NCT05768035 Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide | Hematological Malignancies | unknown | 40 |
| 2025-07 est. | P2/P3 | Gelscom SAS | NCT05969392 Evaluation of Efficacy and Safety of Intradiscal Gelified Ethanol in Refractory Cervical Discogenic Pain | Pain, Cervical; Discogenic Pain | not yet recruiting | 60 |
| 2025-07 est. | P2/P3 | SPA Società Prodotti Antibiotici S.p.A. | NCT06263517 Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients | Osteoarthritis of Knee | unknown | 296 |
| 2025-07 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06412471 A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | First-line Advanced NSCLC Patients | unknown | 235 |
| 2025-07 est. | P1/P2 | Krystal Biotech, Inc. KRYS | NCT06724900 A Study Assessing KB304 for the Treatment of Wrinkles in Women | Wrinkles in Decolletage; Pigmentation; Décolleté Wrinkles | active not recruiting | 19 |
| 2025-07 est. | P2 | Praxis Precision Medicines PRAX | NCT06908356 An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures | Focal Onset Seizure; Primary Generalized Epilepsy | recruiting | 50 |
| 2025-07-01 | P1/P2 | PharmaMar | NCT02611024 Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | Advanced Solid Tumors; Glioblastoma; Soft Tissue Sarcoma (Excluding GIST); Endometrial Carcinoma; Ep | completed | 316 |
| 2025-07-01 | P1/P2 | Incyte Biosciences Japan GK INCY | NCT04661007 To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | Non Hodgkins Lymphoma; Diffuse Large B-cell Lymphoma | active not recruiting | 72 |
| 2025-07-01 | P3 | Takeda TAK | NCT04779307 A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) | Colitis, Ulcerative | completed | 121 |
| 2025-07-01 | P3 | HK inno.N Corporation | NCT04840550 Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs | Preventive Peptic Ulcer | completed | 392 |
| 2025-07-01 | P3 | Telix Pharmaceuticals (Innovations) Pty Ltd TLX | NCT04876651 The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of | Metastatic Prostate Cancer | terminated | 16 |
| 2025-07-01 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06254742 A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malig | Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimen | withdrawn | |
| 2025-07-01 est. | P1/P2 | Empower Research Inc | NCT06471959 Psychedelic-assisted Group Program for First Responders | Psilocybin; Psychotherapy, Group | unknown | 32 |
| 2025-07-01 | P2/P3 | CanSino Biologics Inc. | NCT06708286 A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) | Diphtheria; Tetanus; Pertussis | completed | 1820 |
| 2025-07-02 | P3 | Daiichi Sankyo | NCT04622319 A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Foll | HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer | active not recruiting | 1600 |
| 2025-07-02 | P1/P2 | Sanofi SNY | NCT04717375 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Cancer; Neoplasm | terminated | 125 |
| 2025-07-02 | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05365178 To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-re | HR-positive, HER2-negative Breast Neoplasms | active not recruiting | 432 |
| 2025-07-02 | P2 | Amgen AMGN | NCT05669014 A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myo | Idiopathic Inflammatory Myositis | completed | 12 |
| 2025-07-02 | P2 | argenx ARGX | NCT05810948 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | Lupus Nephritis | completed | 73 |
| 2025-07-02 | P2 | Elios Therapeutics, LLC | NCT06175221 Autologous TLPO Vaccine Basket | Tumor, Solid; Tumor Metastasis; Cancer; Tumor | terminated | 63 |
| 2025-07-03 | P2 | Bayer | NCT00694850 Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associate | Hypertension, Pulmonary | completed | 22 |
| 2025-07-03 | P2 | Janssen Research & Development, LLC | NCT04640623 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsi | Urinary Bladder Neoplasms | active not recruiting | 220 |
| 2025-07-03 | P3 | Aurinia Pharmaceuticals Inc. AUPH | NCT05288855 Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | terminated | 9 |
| 2025-07-03 | P2 | Partner Therapeutics, Inc. | NCT05588609 Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | NSCLC Harboring NRG1 Fusion; Metastatic Castration-resistant Prostate Cancer | terminated | 13 |
| 2025-07-03 | P2 | Pfizer PFE | NCT06712836 A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight | Obesity; Overweight or Obesity | completed | 239 |
| 2025-07-04 | P3 | Gilead Sciences GILD | NCT04527991 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Locally Advanced or Metastatic Unresectable Urothelial Cancer | completed | 711 |
| 2025-07-04 | P3 | Hoffmann-La Roche | NCT04958265 A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome ( | Atypical Hemolytic Uremic Syndrome | active not recruiting | 41 |
| 2025-07-04 | P3 | Aurinia Pharmaceuticals Inc. AUPH | NCT05962788 Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis | Adolescent Lupus Nephritis; Pediatric Lupus Nephritis | terminated | 4 |
| 2025-07-04 | P2 | Beijing Suncadia Pharmaceuticals Co., Ltd | NCT06109831 Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic | Hyperlipidemic | completed | 335 |
| 2025-07-05 est. | P1/P2 | S.Biomedics Co., Ltd. | NCT04818203 A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet | Crow's Feet | recruiting | 80 |
| 2025-07-05 | P1/P2 | Bristol-Myers Squibb BMY | NCT05337137 A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | Carcinoma, Hepatocellular | completed | 82 |
| 2025-07-06 | P1/P2 | CellCentric Ltd. | NCT03568656 Study to Evaluate CCS1477 in Advanced Tumours | Metastatic Castration-Resistant Prostate Cancer; Metastatic Breast Cancer; Non-small Cell Lung Cance | completed | 219 |
| 2025-07-07 | P1/P2 | Jasper Therapeutics, Inc. JSPR | NCT02963064 JSP191 Antibody Targeting Conditioning in SCID Patients | SCID | terminated | 23 |
| 2025-07-07 | P3 | Incyte Corporation INCY | NCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma | terminated | 167 |
| 2025-07-07 | P2/P3 | Vertex Pharmaceuticals Incorporated VERX | NCT03745287 A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease | Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies | completed | 63 |
| 2025-07-07 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT04680988 A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | completed | 194 |
| 2025-07-07 est. | P2 | Biogen BIIB | NCT05764122 A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well | Ischemic Stroke | withdrawn | |
| 2025-07-07 | P3 | 89bio, Inc. | NCT05852431 To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | completed | 369 |
| 2025-07-07 | P3 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT05899179 Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above | Latent Tuberculosis Infection | completed | 780 |
| 2025-07-07 | P2 | Carmot Therapeutics, Inc. | NCT06062069 A Study of CT-868 in Type 1 Diabetes Mellitus | Overweight; Obese; Type 1 Diabetes Mellitus | completed | 111 |
| 2025-07-07 | P2 | Upstream Bio Inc. UPB | NCT06164704 A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 81 |
| 2025-07-07 | P3 | AbbVie ABBV | NCT06241313 Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine | Migraine | completed | 2158 |
| 2025-07-07 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06396429 To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese | Overweight or Obesity | completed | 567 |
| 2025-07-08 | P3 | Biogen BIIB | NCT02283853 Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Relapsing-Remitting Multiple Sclerosis | completed | 156 |
| 2025-07-08 | P3 | Regeneron Pharmaceuticals REGN | NCT05070858 A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthe | Generalized Myasthenia Gravis | active not recruiting | 288 |
| 2025-07-08 | P2 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | NCT05348356 Nirogacestat in Ovarian Granulosa Cell Tumors | Ovarian Granulosa-Stromal Tumor; Ovarian Granulosa Cell Tumor; Ovarian Cancer | completed | 53 |
| 2025-07-08 | P3 | Hoffmann-La Roche | NCT05987423 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease | Thyroid Eye Disease; TED | completed | 131 |
| 2025-07-08 | P1/P2 | ModernaTX, Inc. | NCT05995275 A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Yea | Smallpox; Mpox | completed | 351 |
| 2025-07-08 | P1/P2 | Hoffmann-La Roche | NCT06055075 A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple M | Relapsed or Refractory Multiple Myeloma | terminated | 21 |
| 2025-07-08 | P2 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT06764303 A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | Paroxysmal Nocturnal Hemoglobinuria | active not recruiting | 24 |
| 2025-07-08 | P3 | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd | NCT06949852 Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia | Postoperative Analgesia | completed | 289 |
| 2025-07-09 | P2 | Arcus Biosciences, Inc. RCUS | NCT04262856 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 151 |
| 2025-07-09 | P1/P2 | Syntara | NCT04676529 Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera o | Myelofibrosis; Primary Myelofibrosis (PMF); Post- Essential Thrombocythemia Myelofibrosis; Post Poly | completed | 43 |
| 2025-07-09 | P2 | BioAtla, Inc. BCAB | NCT04681131 CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Non-Small-Cell Lung Cancer | completed | 85 |
| 2025-07-09 | P2 | Regend Therapeutics | NCT05638776 Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy | Chronic Obstructive Pulmonary Disease | completed | 58 |
| 2025-07-09 | P3 | Alexion Pharmaceuticals, Inc. | NCT06079281 Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | Hypophosphatasia | active not recruiting | 124 |
| 2025-07-09 | P2/P3 | Takeda TAK | NCT06741683 A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan | Dengue Fever | completed | 187 |
| 2025-07-10 | P2 | Nanjing Legend Biotech Co. | NCT03758417 A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants W | Multiple Myeloma | terminated | 123 |
| 2025-07-10 | P2 | Leap Therapeutics, Inc. | NCT05480306 Phase 2 Study of DKN-01 in Colorectal Cancer | Colorectal Cancer; Colorectal Adenocarcinoma; Colo-rectal Cancer; Colorectal Cancer Metastatic | completed | 188 |
| 2025-07-10 | P2 | Albireo, an Ipsen Company | NCT05642468 Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | terminated | 18 |
| 2025-07-10 | P2/P3 | RemeGen Co., Ltd. | NCT05980481 A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | Gastric Cancer | active not recruiting | 201 |
| 2025-07-10 | P3 | Dong-A ST Co., Ltd. | NCT06151210 Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis | Gastritis Acute; Gastritis Chronic | completed | 467 |
| 2025-07-10 | P2 | Pfizer PFE | NCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | Breast Cancer | completed | 121 |
| 2025-07-10 | P2 | Vyne Therapeutics Inc. | NCT06493578 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. | Non-segmental Vitiligo | terminated | 205 |
| 2025-07-10 | P3 | Ahn-Gook Pharmaceuticals Co.,Ltd | NCT06717360 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R | Hypercholesterolemia | completed | 158 |
| 2025-07-10 est. | P2 | Cisen Pharmaceutical CO., LTD. | NCT06771063 A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients | Vaginitis | recruiting | 108 |
| 2025-07-10 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07140328 Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary D | Chronic Obstructive Lung Disease (COLD) | recruiting | 50 |
| 2025-07-11 | P3 | Loxo Oncology, Inc. | NCT05023980 A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymp | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | active not recruiting | 282 |
| 2025-07-11 | P3 | InflaRx GmbH IFRX | NCT05964413 Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum | Pyoderma Gangrenosum | terminated | 54 |
| 2025-07-14 | P3 | Bristol-Myers Squibb BMY | NCT05328908 A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | Colorectal Neoplasms | terminated | 769 |
| 2025-07-14 | P2 | AstraZeneca AZN | NCT05809934 A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | Nonalcoholic Steatohepatitis | completed | 220 |
| 2025-07-14 | P2 | Janssen Research & Development, LLC | NCT06083753 Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | completed | 182 |
| 2025-07-14 | P2 | Knoa Pharma LLC | NCT06545929 Study of Sunobinop on Craving in Alcohol Use Disorder | Alcohol Use Disorder | completed | 40 |
| 2025-07-14 | P1/P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06621316 A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects | Overweight or Obesity | completed | 74 |
| 2025-07-15 | P2 | AstraZeneca AZN | NCT05737940 A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 | Pulmonary Hypertension (World Health Organization Group 2); Heart Failure | completed | 260 |
| 2025-07-15 est. | P2 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | NCT06353360 TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | Glioblastoma Multiforme | unknown | 30 |
| 2025-07-15 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06415214 Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes | Diabetic Kidney Disease, Type 2 Diabetes | completed | 281 |
| 2025-07-15 | P3 | Nanjing Zenshine Pharmaceuticals | NCT06669351 Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza | Respiratory Viral Infection | terminated | 98 |
| 2025-07-15 | P2 | Neurocentria, Inc. | NCT06673368 A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT- | ADHD | terminated | 2 |
| 2025-07-15 | P1/P2 | BioNTech SE BNTX | NCT06683352 A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People | Influenza,Human; COVID-19 | completed | 1353 |
| 2025-07-15 | P2 | Taisho Pharmaceutical Co., Ltd. | NCT06745518 A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | Hyperphosphatemia Patients on Hemodialysis | completed | 62 |
| 2025-07-16 | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05060822 Phase ll Study of HEC585 in Patients With IPF | Idiopathic Pulmonary Fibrosis | active not recruiting | 270 |
| 2025-07-16 | P3 | Amgen AMGN | NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | Colorectal Cancer (CRC) | completed | 160 |
| 2025-07-16 | P3 | Genentech, Inc. | NCT05306340 A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Particip | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | active not recruiting | 373 |
| 2025-07-16 | P3 | Cassiopea SpA | NCT05914805 A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) | Alopecia, Androgenetic | completed | 762 |
| 2025-07-16 | P2 | Brii Biosciences Limited | NCT05970289 Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Chronic Hepatitis B Virus Infection | completed | 86 |
| 2025-07-16 | P2 | Pelage Pharmaceuticals, Inc. | NCT06393452 Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA | Androgenetic Alopecia | completed | 78 |
| 2025-07-17 | P3 | Hoffmann-La Roche | NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) | Multiple Sclerosis | completed | 1055 |
| 2025-07-17 | P1/P2 | Sangamo Therapeutics SGMOQ | NCT03653247 A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell D | Sickle Cell Disease | completed | 7 |
| 2025-07-17 | P1/P2 | Hutchison Medipharma Limited | NCT05173142 A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | Solid Tumor | completed | 190 |
| 2025-07-17 | P1/P2 | UCB Biopharma SRL | NCT05277571 A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Stu | Atopic Dermatitis | completed | 109 |
| 2025-07-17 | P3 | Regeneron Pharmaceuticals REGN | NCT05394116 A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossif | Fibrodysplasia Ossificans Progressiva | active not recruiting | 63 |
| 2025-07-17 | P3 | Priovant Therapeutics, Inc. | NCT05437263 A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis | Dermatomyositis | completed | 241 |
| 2025-07-17 est. | P2 | CNBG-Virogin Biotech (Shanghai) Ltd. | NCT06126510 Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma | Sarcoma | recruiting | 40 |
| 2025-07-17 | P1/P2 | Alnylam Pharmaceuticals ALNY | NCT06423352 A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension | Mild to Moderate Hypertension | completed | 36 |
| 2025-07-17 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06990776 A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects | Chronic Hepatitis B | withdrawn | |
| 2025-07-18 | P2 | AbbVie ABBV | NCT02782663 A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease | Crohn's Disease (CD) | completed | 107 |
| 2025-07-18 | P2 | Moleac Pte Ltd. | NCT05289947 MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits | Stroke; Stroke, Ischemic; Strokes Thrombotic; Stroke Sequelae; Stroke, Cardiovascular; Stroke, Embol | completed | 303 |
| 2025-07-18 | P3 | Tetra Discovery Partners | NCT05358886 A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome | Fragile X Syndrome | completed | 171 |
| 2025-07-18 | P1/P2 | BeOne Medicines ONC | NCT05471843 Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL); Relapsed Mantle Cell Lymphoma | active not recruiting | 125 |
| 2025-07-18 | P3 | Pentixapharm AG | NCT06125028 [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma | Marginal Zone Lymphoma | terminated | 8 |
| 2025-07-18 est. | P3 | Yuhan Corporation | NCT06625957 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition | Parenteral Nutrition | recruiting | 60 |
| 2025-07-19 | P2 | Dicot AB | NCT06703840 Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile Dysfunction | Erectile Dysfunction | completed | 156 |
| 2025-07-20 | P2 | Guangdong Raynovent Biotech Co., Ltd | NCT06254274 A Study of RAY1225 in Participants With Type 2 Diabetes | T2DM (Type 2 Diabetes Mellitus) | completed | 210 |
| 2025-07-20 | P3 | Novo Nordisk A/S NVO | NCT06588504 Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Das | Diabetes Mellitus, Type 1 | completed | 38 |
| 2025-07-21 | P3 | Pfizer PFE | NCT05634811 Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children | Lyme Disease | completed | 3547 |
| 2025-07-21 | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06445400 A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Can | HER2-positive Breast Cancer | active not recruiting | 83 |
| 2025-07-21 | P3 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | NCT06975514 Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder | Insomnia Disorder | completed | 61 |
| 2025-07-22 | P3 | Rare Thyroid Therapeutics International AB | NCT05579327 Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) | Monocarboxylate Transporter 8 Deficiency; Allan-Herndon-Dudley Syndrome | completed | 20 |
| 2025-07-22 | P1/P2 | Revelation Biosciences, Inc REVB | NCT06863467 Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease. | Renal Insufficiency, Chronic; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4 | completed | 40 |
| 2025-07-23 | P2 | GlaxoSmithKline | NCT05999799 A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | terminated | 161 |
| 2025-07-23 | P3 | Alexion Pharmaceuticals, Inc. | NCT06079372 Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | Hypophosphatasia | active not recruiting | 43 |
| 2025-07-23 | P3 | RDC Clinical Pty Ltd | NCT06104917 Effect of Maolactin on Gastrointestinal Tract (GIT) Health | Gastrointestinal Dysfunction | completed | 91 |
| 2025-07-23 | P3 | Sanofi SNY | NCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate- | Dermatitis Atopic | completed | 601 |
| 2025-07-23 | P3 | Bionorica SE | NCT06211049 Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea | Primary Dysmenorrhea | completed | 335 |
| 2025-07-24 | P2 | Novartis Pharmaceuticals NVS | NCT04675931 To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria | Severe Malaria | completed | 254 |
| 2025-07-24 | P2 | Novo Nordisk A/S NVO | NCT05405114 Research Study Investigating How Well NDec Works in People With Sickle Cell Disease | Sickle Cell Disease | completed | 96 |
| 2025-07-24 | P2 | Biotheus Inc. | NCT05864105 PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma | Hepatocellular Carcinoma | completed | 35 |
| 2025-07-24 | P2 | ITB-Med LLC | NCT06025110 A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients | Diabetes Mellitus, Type 1 | terminated | 9 |
| 2025-07-24 | P3 | AstraZeneca AZN | NCT06042049 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab | Respiratory Syncytial Virus Infections | completed | 33 |
| 2025-07-24 | P3 | Hoffmann-La Roche | NCT06106828 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease | Thyroid Eye Disease | completed | 127 |
| 2025-07-24 | P2 | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | NCT06602219 A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | completed | 222 |
| 2025-07-24 | P2 | Lynk Pharmaceuticals Co., Ltd | NCT07071610 A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis | Atopic Dermatitis | completed | 75 |
| 2025-07-25 | P3 | Amgen AMGN | NCT03872401 Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | Coronary Heart Disease (CHD) | completed | 12301 |
| 2025-07-25 | P3 | Eli Lilly and Company LLY | NCT05869903 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight; Overweight or Obesity | active not recruiting | 3127 |
| 2025-07-25 | P2 | Immunovant Sciences GmbH IMVT | NCT05907668 A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease | Graves Disease | completed | 32 |
| 2025-07-25 | P2 | Neurocrine Biosciences NBIX | NCT06267846 A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 73 |
| 2025-07-27 | P3 | National Vaccine and Serum Institute, China | NCT05916326 Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha) | Norovirus Infections; Norwalk Gastroenteritis | completed | 8000 |
| 2025-07-27 | P2 | TransThera Sciences (Nanjing), Inc. | NCT06057571 Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor | Cholangiocarcinoma Metastatic | active not recruiting | 50 |
| 2025-07-27 | P3 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | NCT06710925 A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants | Respiratory Syncytial Virus Infections | completed | 315 |
| 2025-07-28 | P2 | BrainX Corporation | NCT03413384 To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia | Parkinson's Disease Dementia | completed | 100 |
| 2025-07-28 | P3 | AstraZeneca AZN | NCT04053634 Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | Chronic Obstructive Pulmonary Disease | completed | 689 |
| 2025-07-28 | P2/P3 | ModernaTX, Inc. | NCT05127434 A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age | Respiratory Syncytial Virus | completed | 36814 |
| 2025-07-28 | P1/P2 | Takeda TAK | NCT05220098 First-in-Human Study of TAK-280 in Participants With Solid Tumors | Unresectable Locally Advanced or Metastatic Cancer | terminated | 69 |
| 2025-07-28 | P2 | Takeda TAK | NCT05526391 A Study of TAK-341 in Treatment of Multiple System Atrophy | Multiple System Atrophy | completed | 158 |
| 2025-07-28 | P3 | Pathalys Pharma | NCT05832931 Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 | Secondary Hyperparathyroidism; End-stage Kidney Disease (ESKD) | completed | 362 |
| 2025-07-28 | P3 | Merck Sharp & Dohme LLC MRK | NCT05952856 A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids | Hypercholesterolemia; Familial Hypercholesterolemia | completed | 2912 |
| 2025-07-28 | P1/P2 | Windtree Therapeutics | NCT05975021 A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C | Cardiogenic Shock | active not recruiting | 20 |
| 2025-07-28 | P2 | CinPhloro Pharma, LLC | NCT06153420 Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). | Irritable Bowel Syndrome With Diarrhea | terminated | 421 |
| 2025-07-28 | P2 | Dianthus Therapeutics DNTH | NCT06282159 A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | Myasthenia Gravis, Generalized | active not recruiting | 65 |
| 2025-07-28 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06554184 HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | completed | 706 |
| 2025-07-28 | P3 | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. | NCT06717152 Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease | Dry Eye | completed | 427 |
| 2025-07-28 | P2 | AstraZeneca AZN | NCT06750276 A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. | Liver Fibrosis; Hepatic Cirrhosis | completed | 40 |
| 2025-07-29 | P2 | Merck Sharp & Dohme LLC MRK | NCT04740307 Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK | Advanced Hepatocellular Carcinoma | completed | 116 |
| 2025-07-29 | P3 | Bristol-Myers Squibb BMY | NCT04810078 A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has S | Clear Cell Renal Cell Carcinoma | active not recruiting | 681 |
| 2025-07-29 | P1/P2 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05781399 First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria | Phenylketonuria | completed | 163 |
| 2025-07-29 | P3 | Boehringer Ingelheim | NCT06214741 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight | Obesity; Overweight | completed | 307 |
| 2025-07-29 | P2 | GlaxoSmithKline | NCT06447506 Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. | Dermatitis, Atopic | terminated | 79 |
| 2025-07-29 est. | P2 | Empros Pharma AB | NCT06993428 A Trial With EMP16 in Preparation for Late Phase Studies | Overweight or Obese; Obesity and Overweight | not yet recruiting | 39 |
| 2025-07-29 | P2 | Eli Lilly and Company LLY | NCT07030868 A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | Obesity; Overweight; Type 2 Diabetes | terminated | 1 |
| 2025-07-30 | P1/P2 | VBI Vaccines Inc. | NCT03382977 Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Glioblastoma Multiforme | terminated | 70 |
| 2025-07-30 | P2 | Takeda TAK | NCT03635073 A Study of Soticlestat in Adults and Children With Rare Epilepsies | Epilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) | terminated | 156 |
| 2025-07-30 est. | P3 | LIB Therapeutics LLC | NCT04798430 Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction | Cardiovascular Disease With Mention of Arteriosclerosis; Elevated Cholesterol; Familial Hypercholest | unknown | 2000 |
| 2025-07-30 est. | P3 | Incepta Pharmaceuticals Ltd | NCT05056558 Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 | Covid19 | withdrawn | |
| 2025-07-30 | P2 | TC Biopharm | NCT05358808 ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Rel | Acute Myeloid Leukemia; Myelodysplastic Syndromes | terminated | 16 |
| 2025-07-30 | P1/P2 | Cellbion Co., Ltd. | NCT05547061 A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Cast | Prostate Cancer; mCRPC | completed | 91 |
| 2025-07-30 est. | P1/P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05719701 Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma | unknown | 80 |
| 2025-07-30 est. | P3 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT05755048 FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer | Breast Cancer | unknown | 314 |
| 2025-07-30 est. | P3 | Suzhou Puhe Pharmaceutical Technology Co., LTD | NCT05767892 YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | 350 |
| 2025-07-30 est. | P3 | Luye Pharma Group Ltd. | NCT05853354 Comparative Efficacy, Safety, PK, and Immunogenicity Study | Osteoporosis, Postmenopausal | active not recruiting | 392 |
| 2025-07-30 est. | P3 | NLS Pharmaceutics | NCT05914194 A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 | Narcolepsy Type 1; Narcolepsy With Cataplexy | unknown | 48 |
| 2025-07-30 est. | P1/P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT05970016 A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | Patients with Advanced Solid Tumors | recruiting | 56 |
| 2025-07-30 | P2 | Merck Sharp & Dohme LLC MRK | NCT06161116 Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) | Systemic Lupus Erythematosus | terminated | 149 |
| 2025-07-30 | P3 | Bio-Thera Solutions | NCT06280196 A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC | Carcinoma, Non-Small-Cell Lung | terminated | 162 |
| 2025-07-30 est. | P2 | MindRank AI Ltd | NCT06606483 A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight | Obesity; Overweight and Obesity | unknown | 300 |
| 2025-07-30 | P2 | Spinogenix | NCT06833281 Extension Study of Participants From SPG302-ALZ-101 | Alzheimer's Disease | terminated | 12 |
| 2025-07-30 | P2 | Jiangsu Nhwa Pharmaceutical Co., Ltd. | NCT06842992 A Phase II Study to Evaluate NH102 for Depression | Major Depressive Disorder (MDD) | completed | 243 |
| 2025-07-30 | P2 | CAGE Bio Inc. | NCT06923228 A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis | Atopic Dermatitis (AD) | completed | 3 |
| 2025-07-30 | P3 | JW Pharmaceutical | NCT06955104 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia | Dyslipidemia | completed | 145 |
| 2025-07-31 | P1/P2 | Vyriad, Inc. | NCT03647163 Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | Solid Tumor; Non Small Cell Lung Cancer; Neuroendocrine Carcinoma; Renal Cell Carcinoma (RCC) | active not recruiting | 33 |
| 2025-07-31 | P1/P2 | Heartseed Inc. | NCT04945018 A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) | Heart Failure; Ischemic Heart Disease | completed | 10 |
| 2025-07-31 | P2/P3 | InnoPharmax Inc. | NCT05065957 Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | Biliary Tract Cancer | terminated | 19 |
| 2025-07-31 | P3 | Tanabe Pharma Corporation | NCT05198557 A Study of MT-0551 in Patients With Systemic Sclerosis | Systemic Sclerosis | active not recruiting | 80 |
| 2025-07-31 est. | P2 | Epitopoietic Research Corporation | NCT05366062 ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | Glioma, Malignant | unknown | 28 |
| 2025-07-31 est. | P3 | Sinocelltech Ltd. | NCT05480293 This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD | Wet Age-related Macular Degeneration | unknown | 446 |
| 2025-07-31 est. | P2 | Hrain Biotechnology Co., Ltd. | NCT05594797 Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM | Multiple Myeloma | recruiting | 100 |
| 2025-07-31 | P2 | QBiotics Group Limited | NCT05608876 A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | Head and Neck Cancer | active not recruiting | 15 |
| 2025-07-31 | P3 | Amgen AMGN | NCT05633355 A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 187 |
| 2025-07-31 | P2 | InventisBio Co., Ltd | NCT05665699 Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout | Gout | completed | 80 |
| 2025-07-31 est. | P3 | Shanghai JMT-Bio Inc. | NCT05838066 Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | 880 |
| 2025-07-31 | P3 | Luye Pharma Group Ltd. | NCT05970510 A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. | Generalized Anxiety Disorder | completed | 555 |
| 2025-07-31 | P3 | AbbVie ABBV | NCT06137287 A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants | Masseter Muscle Prominence | completed | 259 |
| 2025-07-31 est. | P1/P2 | CytosinLab Therapeutics Co., Ltd. | NCT06224387 CTS2190 Phase I /II Clinical Study in Patients | Solid Tumors; Pancreatic Cancer; Non-small Cell Lung Cancer; Triple-negative Breast Cancer | unknown | 224 |
| 2025-07-31 | P1/P2 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06226766 JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Advanced Solid Tumor | terminated | 11 |
| 2025-07-31 est. | P2 | SHINKEI Therapeutics, Inc | NCT06253923 Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI). | Traumatic Brain Injury | active not recruiting | 45 |
| 2025-07-31 | P1/P2 | Jasper Therapeutics, Inc. JSPR | NCT06353971 A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urt | Chronic Inducible Urticaria | terminated | 27 |
| 2025-07-31 est. | P2 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06413615 A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors | Advanced Solid Tumor | unknown | 150 |
| 2025-07-31 | P2 | Vertanical GmbH | NCT06475001 Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain | Chronic Non-specific Low Back Pain | completed | 652 |
| 2025-07-31 est. | P3 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06569420 Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | Non-Small Cell Lung Cancer; ALK-positive; SAF-189s | active not recruiting | 275 |
| 2025-07-31 | P3 | Chengdu Suncadia Medicine Co., Ltd. | NCT06593938 A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor T | Paroxysmal Nocturnal Hemoglobinuria | completed | 76 |
| 2025-07-31 | P2 | Akeso | NCT06700499 A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 450 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.